REFERENCES
- Salles G, Barrett M, Foà R, et al. Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x
- Cang S, Mukhi N, Wang K, et al. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5(1):64. doi:10.1186/1756-8722-5-64
- Banchereau J, Rousset F. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv Immunol. 1992;52(C):125–262. doi:10.1016/S0065-2776(08)60876-7
- European Medicines Agency (EMA ). An overview of Libtayo and why it is authorised in the EU What is Libtayo and what is it used for ? 2018;44(0):1–2. https://www.ema.europa.eu/en/documents/overview/mylotarg-epar-summary-public_en.pdf.
- Boffetta P. I. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol. 2011;22(Supplement 4):iv27–iv31. doi:10.1093/annonc/mdr167
- Hallek M, Information CME. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–460. doi:10.1002/ajh.23979
- Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii83–iii92. doi:10.1093/annonc/mdu264
- Hassan RI, Gaffo AL. Rituximab in ANCA-Associated vasculitis. Curr Rheumatol Rep. 2017;19(2):6. doi:10.1007/s11926-017-0632-1
- Annex I. Ifla J. 1994;20(3):338–340. doi:10.1177/034003529402000315
- Gorris E. Annex I: power Polit Neo-Elamite Kingdom. 2021;:241–255. doi:10.2307/j.ctv1q26vdb.13
- Bomm L, Fracaroli TS, Sodré JL, et al. Off-label use of rituximab in dermatology: pemphigus treatment. An Bras Dermatol. 2013;88(4):676–678. doi:10.1590/abd1806-4841.20131905
- Van Allen EM, Miyake T, Gunn N, et al. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract. 2011;7(2):76–79. doi:10.1200/JOP.2010.000042
- Abramson JS. Diagnosis and management of castleman disease. J Natl Compr Canc Netw. 2019;17(11.5):1417–1419. doi:10.6004/jnccn.2019.5037
- mabthera @ https://www.ema.europa.eu. https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera.
- Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs. 2014;6(4):820–837. doi:10.4161/mabs.29105
- Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15(3):343–352. doi:10.1016/S1470-2045(14)70005-1
- Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3(3):e128–e138. doi:10.1016/S2352-3026(16)00004-1
- Jurczak W, Długosz Danecka M, Buske C. Rituximab biosimilars for lymphoma in Europe. Expert Opin Biol Ther. 2019;19(10):1045–1056. doi:10.1080/14712598.2019.1665017
- subst. @ www.mp.pl. https://www.mp.pl/pacjent/leki/subst.html?id=1069.
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580676/.
- Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for clinical cancer research (SAKK. Ann Oncol. 2005;16(10):1675–1682.) doi:10.1093/annonc/mdi320
- Kasi PM, Tawbi HA, Oddis CV, et al. Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective. Crit Care. 2012;16(4):231. doi:10.1186/cc11304
- Otremba B, Borchardt J, Kuske A, et al. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany. Future Oncol. 2020;16(15):1001–1012. doi:10.2217/fon-2020-0180
- Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–e361. doi:10.1016/S2352-3026(17)30106-0
- Lee S, Lee H, Kim EY. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and Non-Hodgkin’s lymphoma: a systematic review and meta-analysis. BioDrugs. 2019;33(5):469–483. doi:10.1007/s40259-019-00376-z
- Jurczak W, Cohen S, Illidge TM, et al. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. Future Oncol. 2019;15(36):4223–4234. doi:10.2217/fon-2019-0430
- Jurczak W, Ilidia M, Govindbabu KS, et al. A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 Versus rituximab in patients with previously untreated advanced follicular lymphoma. Blood. 2016;128(22):1809–1809. doi:10.1182/blood.V128.22.1809.1809
- Carpenter L, Nikiphorou E, Kiely P POSTER VIEWING _ III Thursday 2 May 2019 Downloaded from, et al. https://academic.oup.com/rheumatology/article/58/Supplement_3/kez107.031/5444699 by University of Glasgow user on 22. August 2020 iii130 Thursday 2 May 2019 POSTER VIEWING _ III Downloaded from https. 2019;(May):129-130.
- McBride A, Daniel S, Driessen MT, et al. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: a real-world UK study. Leuk Res. 2021;111(April):106671. doi:10.1016/j.leukres.2021.106671
- Kurki P, Barry S, Bourges I, et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81(16):1881–1896. doi:10.1007/s40265-021-01601-2
- Welslau M, Marschner NW, Otremba BJ, et al. REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2020;38(15_suppl):8060–8060. doi:10.1200/JCO.2020.38.15_suppl.8060
- https://ilina @ library.ehaweb.org. https://library.ehaweb.org/eha/2019/24th/267883/ilina.micheva.efficacy.and.safety.of.rituximab.biosimilar.truxima.in.patients.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1550.
- Urru SAM, Spila Alegiani S, Guella A, et al. Safety of switching between rituximab biosimilars in onco-hematology. Sci Rep. 2021;11(1):5956. doi:10.1038/s41598-021-85563-1
- Ogura M, Sancho JM, Cho SG, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018;5(11):e543–e553. doi:10.1016/S2352-3026(18)30157-1
- Keerty D, Ananthaneni A, Ramadas P, et al. Comparison of adverse event profiles of rituximab, rituximab hycela and rituximab biosimilars: a real-world pharmacovigilance database analysis. Blood. 2022;140(Supplement 1):13196–13197. doi:10.1182/blood-2022-167269
- Baer WH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7(5):530–544. doi:10.3390/ph7050530
- Cheesman S. Introduction of biosimilar rituximab: a hospital perspective. Hemasphere. 2021;5(1):E515. doi:10.1097/HS9.0000000000000515
- Hübel K, Kron F, Lux MP. Biosimilars in oncology: Effects on economy and therapeutic innovations. Eur J Cancer. 2020;139:10–19. doi:10.1016/j.ejca.2020.07.037
- U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Cancer Ther Eval Progr. 2017:155. http://upen.terengganu.gov.my/index.php/2017.